49 completed, 7 terminated, 3 unknown, 1 recruiting. 62 Phase 2, 8 Phase 1, 7 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 62 | Completed 49, Terminated 7, Unknown 3, Recruiting 1, Suspended 1, Withdrawn 1 |
| Phase 1 | 8 | Completed 6, Suspended 1, Terminated 1 |
| Phase 3 | 7 | Completed 7 |
Follow Schizoaffective Disorder: new trials by email Literature Review of Schizoaffective Disorder trials Research Report on Schizoaffective Disorder
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Assessment of Acute Psychomotor Agitation Measures Associated With Schizophrenia and Bipolar Disorder BXCL501 Sublingual Film - Bipolar I Disorder, Bipolar II Disorder | Phase 2 | Completed | BioXcel Therapeutics Inc | 33 | 2025-06-19 | 2026-10-05 |
| Accelerated TMS in Psychosis repetitive Transcranial Magnetic Stimulation (rTMS) - Schizophrenia, Schizoaffective Disorder | Phase 1 / Phase 2 | Suspended | Beth Israel Deaconess Medical Center | 20 | 2022-11-29 | 2026-04-22 |
| Sodium Nitroprusside in Early Course Schizophrenia Sodium Nitroprusside, 5% Dextrose solution - Schizophrenia, Schizoaffective Disorder | Phase 2 | Terminated | Beth Israel Deaconess Medical Center | 1 | 2022-03-14 | 2025-12-30 |
| Synbiotic Compound to Reduce Symptoms of Schizophrenia Synbiotic Supplement, Inert Compound - Schizophrenia, Schizoaffective Disorder | Phase 2 | Recruiting | Sheppard Pratt Health System | 68 | 2022-02-21 | 2026-04-07 |
| Memantine Augmentation of Targeted Cognitive Training in Schizophrenia Memantine, Placebo - Schizophrenia, Schizoaffective Disorder | Phase 2 / Phase 3 | Completed | University of California, San Diego | 62 | 2021-07-06 | 2026-05-18 |
| Pharmacologic Augmentation of Targeted Cognitive Training in Schizophrenia d-amphetamine, Placebo - Schizophrenia, Schizoaffective Disorder | Phase 2 | Completed | University of California, San Diego | 68 | 2020-11-09 | 2025-12-17 |
| The Effects of Kynurenine Aminotransferase Inhibition in People With Schizophrenia N-acetylcysteine (NAC), Placebo, Tryptophan - Schizophrenia, Schizoaffective Disorder | Phase 1 / Phase 2 | Completed | University of Maryland, Baltimore | 88 | 2020-01-20 | 2026-02-11 |
| Sodium Benzoate and/or N-Acetylcysteine Added to TAU in Patients With Early Schizophrenia Spectrum Disorder. Sodium Benzoate, N-Acetylcysteine, Placebo - Schizophrenia, Schizophreniform Disorders | Phase 2 | Completed | Pakistan Institute of Living and Learning | 64 | 2019-01-01 | 2022-04-27 |
| Sulforaphane to Reduce Symptoms of Schizophrenia Sulforaphane Nutraceutical, Identical-appearing Placebo - Schizophrenia, Schizoaffective Disorder | Phase 2 | Completed | Sheppard Pratt Health System | 64 | 2017-02-22 | 2021-07-27 |
| Cannabidiol Treatment in Patients With Early Psychosis Cannabidiol, Placebo - Schizophrenia, Schizoaffective Disorder | Phase 2 | Completed | Yale University | 18 | 2016-01-28 | 2022-09-06 |
| Pentosan Polysulfate Sodium and Meclofenamic Acid as Treatments in Patients With Psychotic Disorders Meclofenamic acid, Pentosan polysulfate sodium - Psychotic Disorders, Schizophrenia | Phase 2 | Completed | The University of Texas Health Science Center, Houston | 8 | 2015-08-07 | 2019-03-26 |
| A Study to Assess the Clinical Utility of Antipsychotic Medication Levels in Plasma as Determined by Liquid Chromatography-Tandem Mass Spectrometry Aripiprazole, Olanzapine, Paliperidone - Schizophrenia, Schizoaffective Disorder | Phase 2 | Terminated | Janssen Research & Development, LLC | 9 | 2015-05-01 | 2017-03-29 |
| Targeted Vitamin D Treatment of Schizophrenia-Associated Hyperprolinemia Cholecalciferol, Placebo - Schizophrenia, Schizoaffective Disorder | Phase 2 | Withdrawn | NYU Langone Health | 2015-02-01 | 2015-10-12 | |
| Galantamine and Memantine Combination for Cognitive Impairments in Schizophrenia Galantamine ER, Memantine XR - Schizophrenia, Schizoaffective Disorder | Phase 2 | Terminated | Sheppard Pratt Health System | 3 | 2014-09-01 | 2017-11-09 |
| Effect of MMFS-202-302 on Cognitive Enhancement in Schizophrenia MMFS-202-302, Placebo - Schizophrenia, Schizoaffective Disorder | Phase 2 | Completed | Northwestern University | 60 | 2014-08-01 | 2025-06-22 |
| Effectiveness of Adherence Therapy for Schizophrenia Adherence therapy - Schizophrenia, Schizophreniform Disorder | Phase 1 / Phase 2 | Completed | The Hong Kong Polytechnic University | 134 | 2013-05-01 | 2016-02-19 |
| Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and Adolescents Latuda© - Schizophrenia, Schizoaffective Disorder | Phase 2 | Completed | University of North Carolina, Chapel Hill | 9 | 2012-12-01 | 2017-06-14 |
| Kuvan in People With Schizophrenia and Schizoaffective Disorder Kuvan, Multivitamin - Schizophrenia, Schizoaffective Disorder | Phase 1 / Phase 2 | Completed | New York State Psychiatric Institute | 27 | 2012-10-01 | 2017-09-13 |
| POC Study of Pipamperone Added to Stable Treatment With RIS or PAL in Chronic Schizophrenia Pipamperone, Placebo - Chronic Schizophrenia, Schizoaffective Disorder | Phase 2 | Completed | PharmaNeuroBoost N.V. | 7 | 2012-03-01 | 2014-11-19 |
| N-methyl-D-aspartic Acid (NMDA) and Cognitive Remediation in Schizophrenia D-serine, placebo, Sensory Based remediation paradigm - Schizophrenia, Schizoaffective Disorder | Phase 2 | Unknown | Nathan Kline Institute for Psychiatric Research | 16 | 2012-03-01 | 2012-10-25 |
Showing 20 of 62. Sign in to see all of them.
Psychotic Disorders (62) · Schizophrenia (58) · Bipolar Disorder (11) · Mental Disorders (5) · Smoking (3) · Cognitive Dysfunction (2) · Depression (2) · Mania (2) · Mood Disorders (2) · Obesity (2) · Smoking Cessation (2) · Affective Disorders, Psychotic (1) · Asperger Syndrome (1) · Autism Spectrum Disorder (1) · Autistic Disorder (1)
Schizophrenia Spectrum and Other Psychotic Disorders (62) · Mental Disorders (57) · Bipolar and Related Disorders (11) · Behavior (9) · Mood Disorders (9) · Pathological Conditions, Signs and Symptoms (7) · Signs and Symptoms (6) · Nervous System Diseases (5) · Neurologic Manifestations (5) · Behavioral Symptoms (4) · Neurobehavioral Manifestations (4) · Nutritional and Metabolic Diseases (4) · Metabolic Diseases (3) · Body Weight (2) · Cardiovascular Diseases (2)
Estradiol (3) · bifeprunox (3) · Acetylcysteine (2) · Aripiprazole (2) · Cannabidiol (2) · Memantine (2) · Olanzapine (2) · Paliperidone Palmitate (2) · Quetiapine Fumarate (2) · Risperidone (2) · Therapeutics (2) · Transcranial Magnetic Stimulation (2) · ziprasidone (2) · 3-(2,4-dimethoxybenzylidene)anabaseine (1) · Asian ginseng (1)
Nathan Kline Institute for Psychiatric Research (3) · Sheppard Pratt Health System (3) · Solvay Pharmaceuticals (3) · The Alfred (3) · University of Maryland, Baltimore (3) · University of Pittsburgh (3) · VA Office of Research and Development (3) · Beth Israel Deaconess Medical Center (2) · Manhattan Psychiatric Center (2) · New York State Psychiatric Institute (2) · Pakistan Institute of Living and Learning (2) · US Department of Veterans Affairs (2) · University of California, San Diego (2) · Yale University (2) · Bayside Health (1)
United States (46) · Australia (4) · Israel (3) · Canada (2) · Pakistan (2) · Belgium (1) · Germany (1) · Hong Kong (1) · India (1) · Malaysia (1) · Moldova (1) · Norway (1) · Philippines (1) · Puerto Rico (1) · Romania (1)
Jayashri Kulkarni, MBBS, MPM, FRANZCP, PhD (3) · Faith Dickerson, PhD, MPH (2) · Aaron T Beck, MD (1) · Alan Breier, MD (1) · Amy L Drapalski, PhD (1) · Andreas Bechdolf, PD Dr. (1) · Andrew Cutler, MD (1) · Arielle D. Stanford, MD (1) · Armando J Rotondi (1) · Beth L Murphy, MD/PhD (1) · BioXcel MM (1) · Brian A Fallon, MD (1) · Christine Marx, MD MA (1) · Daniel C Javitt, MD, PhD (1)
PMID 11483142, PMID 12823166, PMID 15870612, PMID 16095473, PMID 16131943, PMID 16571581, PMID 16680620, PMID 16737798, PMID 17898352, PMID 18678800, PMID 19818257, PMID 20810586, PMID 21346616, PMID 21969420, PMID 22446565, PMID 22795211, PMID 23782463, PMID 25313530, PMID 26072311, PMID 26457385, PMID 26911397, PMID 27089154, PMID 28318835, PMID 28705532, PMID 28825423, PMID 29619533, PMID 30542300, PMID 31233321, PMID 31414842, PMID 33234053, PMID 33609856, PMID 34817851, PMID 35395548, PMID 36892916, PMID 39144112
P50MH086383 (1), R01MH059807 (1), R01MH061412 (1), R01MH063484 (1), R01MH072556 (1), R21DA030763 (1)